Cirrhosis is advanced chronic scarring and architectural distortion of the liver in which healthy hepatic tissue is progressively replaced by fibrotic tissue and regenerative nodules. It is not simply another word for mild liver scarring: cirrhosis represents a major structural transformation that can impair blood flow through the liver and progressively reduce its functional reserve.
It may arise from many chronic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, chronic hepatitis B or C, autoimmune liver disorders, cholestatic disorders, inherited metabolic conditions and other long-standing causes of hepatic injury. Early cirrhosis may produce few or no symptoms, meaning that substantial structural disease can exist before a person becomes aware of it.
The development of cirrhosis is a dynamic process rather than a single event. Persistent hepatocyte injury activates inflammatory pathways and hepatic stellate cells, which produce excessive extracellular matrix and collagen. Fibrous septa progressively divide the liver into abnormal regenerative nodules, disrupting normal sinusoidal blood flow and communication between hepatocytes and the circulation. This architectural distortion contributes to increased resistance to portal blood flow, producing portal hypertension, while loss of functioning hepatocyte mass impairs metabolic, synthetic and detoxification functions. Cirrhosis can therefore be understood as the combined consequence of fibrosis, vascular remodelling, altered liver architecture and declining functional reserve. The exact balance between inflammation, fibrosis and functional impairment varies between individuals and causes.
Clinicians often distinguish compensated from decompensated cirrhosis. In compensated disease, the liver may retain sufficient functional capacity that major complications such as ascites, variceal bleeding or hepatic encephalopathy have not developed. Decompensation occurs when complications reflecting major loss of hepatic reserve or portal-hypertension consequences appear. Ascites, gastrointestinal variceal bleeding, hepatic encephalopathy and jaundice are important manifestations. Other complications include oedema, bacterial infections, malnutrition, bone disease, kidney dysfunction and hepatocellular carcinoma. A person may move from compensated to decompensated disease following infection, bleeding, alcohol exposure, medication-related injury or progression of the underlying disease. This distinction is clinically important because prognosis, monitoring intensity and transplant assessment change substantially once decompensation develops.
Diagnosis of cirrhosis combines history, examination, laboratory testing and imaging rather than relying on one universal test. Blood tests can identify abnormalities in aminotransferases, bilirubin, albumin, platelet count and clotting parameters and can help investigate the underlying cause. Ultrasound, computed tomography and magnetic resonance imaging can reveal structural changes, portal-hypertension features or complications. Elastography measures liver stiffness and can help estimate fibrosis severity without requiring an invasive procedure.
Liver biopsy remains useful in selected uncertain cases and can directly demonstrate fibrosis and architectural changes microscopically. Modern evaluation often combines non-invasive fibrosis scores, blood markers and elastography to reduce unnecessary biopsy. The diagnostic objective is not merely to label cirrhosis but to establish its cause, stage its severity and identify complications.
Treatment of cirrhosis is directed at the underlying cause, prevention and management of complications, and preservation of remaining liver function. There is no single medicine that reverses established cirrhosis in every patient, but removing the causal injury can slow or sometimes substantially improve disease trajectory, particularly before advanced architectural damage becomes fixed.
Treatment may include antiviral therapy for certain viral infections, sustained alcohol abstinence for alcohol-associated disease, metabolic risk reduction for steatotic liver disease, immunomodulatory treatment for selected autoimmune conditions and specific therapies for inherited or cholestatic disorders. Complications require separate management, including measures to reduce variceal bleeding risk, treatment of ascites, management of hepatic encephalopathy and surveillance for liver cancer.
Portal hypertension is one of the defining physiological consequences of advanced cirrhosis. Scar tissue and altered sinusoidal architecture increase resistance to blood flowing from the portal venous system through the liver. Pressure therefore rises within the portal circulation, encouraging blood to bypass the liver through collateral veins. These collateral vessels can become varices in the oesophagus, stomach and other locations and may rupture, producing life-threatening gastrointestinal bleeding.
Portal hypertension also contributes to splenomegaly and low platelet counts, ascites and other circulatory changes. Cirrhosis can simultaneously impair albumin synthesis, alter sodium and water handling and promote systemic vasodilation, making fluid accumulation more likely. Thus portal hypertension and hepatic synthetic dysfunction interact rather than operating as isolated abnormalities.
Cirrhosis also changes the body's handling of medicines, nutrients, hormones and toxins. Reduced hepatic metabolism can increase exposure to drugs that are normally extensively processed by the liver, while impaired bile production or flow can affect absorption of fat-soluble vitamins. Reduced synthesis of albumin changes protein binding and contributes to oedema, while impaired production of clotting factors contributes to bleeding abnormalities, although coagulation in cirrhosis is more complex than simply being unable to clot.
Malnutrition and muscle wasting are common in advanced disease and can worsen functional reserve. Hepatic encephalopathy results from altered neurotoxin handling and changes in brain function, producing confusion, altered sleep patterns, personality or behaviour changes and, in severe cases, coma. These systemic effects explain why cirrhosis is a multisystem disorder rather than merely a scarred liver.
A major misconception is that cirrhosis necessarily means immediate liver failure. Some people live for years with compensated cirrhosis, particularly when the underlying cause is successfully controlled and complications are prevented. Conversely, cirrhosis is not a benign form of fibrosis: it represents advanced structural disease and substantially increases the risks of portal hypertension, liver failure and hepatocellular carcinoma. Cirrhosis also does not have a single cause, and neither alcohol use nor viral hepatitis explains every case. Long-term management therefore requires identifying the specific cause, monitoring liver function and complications, preventing avoidable additional injury and assessing cancer risk. In advanced disease, liver transplantation may become the definitive treatment when liver function can no longer adequately support the body.
